Aarhus University Seal / Aarhus Universitets segl

Continuous Neuromuscular Blockade Following Successful Resuscitation From Cardiac Arrest: A Randomized Trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Ari Moskowitz, Beth Israel Deaconess Medical Center
  • ,
  • Lars W Andersen
  • Jon C Rittenberger, Department of Emergency Medicine Guthrie Robert Packer Hospital Sayre PA.
  • ,
  • Robert Swor, Beaumont Health System, Royal Oak, MI, USA.
  • ,
  • Raghu R Seethala, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA
  • ,
  • Michael C Kurz, Department of Emergency Medicine University of Alabama School of Medicine Birmingham AL.
  • ,
  • Katherine M Berg, Beth Israel Deaconess Medical Center
  • ,
  • Maureen Chase, Beth Israel Deaconess Medical Center
  • ,
  • Michael N Cocchi, Beth Israel Deaconess Medical Center
  • ,
  • Anne V Grossestreuer, Beth Israel Deaconess Medical Center
  • ,
  • Xiaowen Liu, Beth Israel Deaconess Medical Center
  • ,
  • Mathias J Holmberg
  • Clifton W Callaway, Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • ,
  • Michael W Donnino, Beth Israel Deaconess Medical Center

Background Neuromuscular blockade (NMB) agents are often administered to control shivering during targeted temperature management following cardiac arrest. In this study, we hypothesized that early, continuous NMB would result in a greater reduction in serum lactate levels among comatose patients after cardiac arrest. Methods and Results Randomized trial of continuous NMB for 24 hours versus usual care following cardiac arrest conducted at 5 urban centers in the United States. Adult patients who achieved return of spontaneous circulation, remained unresponsive, and underwent targeted temperature management after cardiac arrest were included. The primary outcome was change in lactate over 24 hours. A total of 83 patients were randomized, and 80 were analyzed (37 and 43 in the NMB and usual care arms, respectively). There was no significant interaction between time and treatment group with respect to change in lactate over 24 hours (median lactate change from 4.2 to 2.0 mmol/L [-2.2 mmol/L] in the NMB arm versus 4.0 to 1.7 mmol/L [-2.3 mmol/L] in the usual care arm; geometric mean difference, 1.3 [95% CI, 1.0-1.8]; P=0.07 for the interaction term). There was no difference in hospital survival (38% [NMB] versus 33% [usual care]; P=0.63) or survival with good functional outcome (30% [NMB] versus 21% [usual care]; P=0.35). There were no adverse events in either arm attributed to study interventions. Conclusions Continuous NMB compared with usual care did not reduce lactate over the first 24 hours after enrollment compared with usual care. There was no difference in overall hospital survival, hospital survival with good neurologic outcome, or adverse events. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02260258.

Original languageEnglish
Article numbere017171
JournalJournal of the American Heart Association
Volume9
Issue17
ISSN2047-9980
DOIs
Publication statusPublished - 2020

See relations at Aarhus University Citationformats

ID: 195542241